UroGen Pharma (URGN) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
UroGen Pharma (URGN) PT Lowered to $36 at Raymond James
March 11, 2025 9:47 AM EDTRaymond James analyst Reni Benjamin lowered the price target on UroGen Pharma (NASDAQ: URGN) to $36.00 (from $40.00) while maintaining a Outperform rating.
The analyst comments "4Q Jelmyto sales of $24.6M were a bit below $25.6M consensus estimate. We should soon... More
